Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1385648

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1385648

Toxoplasmosis Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED:
PAGES: 238 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global toxoplasmosis testing market is anticipated to soar from US$ 1.9 billion in 2024 to a substantial US$ 3 billion by the end of 2031, this market reflects the increasing significance of comprehensive prenatal care and awareness of toxoplasmosis-related maternal and fetal health concerns.

Toxoplasmosis Testing at the Forefront: Toxoplasmosis, especially during pregnancy, has emerged as a significant healthcare concern due to its potential to induce severe complications for both mothers and fetuses. The comprehensive assessment of Toxoplasma gondii infection, primarily through serological testing, played a dominant role in the global market in 2022, capturing a substantial 46.2% value share.

A Vital Component of Infectious Disease Diagnostics: The revenue generated from toxoplasmosis testing accounted for a noteworthy 5.4% share of the global infectious disease diagnostics market in 2022. As the incidence of toxoplasmosis rises, driven by factors like urbanization, population growth, and increased exposure to the Toxoplasma parasite through various transmission pathways, the demand for robust testing and comprehensive diagnostics strategies continues to escalate.

Why is Toxoplasmosis Testing on the Rise Globally? "Rising Incidence and Increased Awareness During Pregnancy" The rapid surge in toxoplasmosis cases globally is a significant cause for concern. This increase is driven by factors like population growth, urbanization dynamics, and heightened exposure to the Toxoplasma parasite through various transmission vectors. Contaminated food and water sources further compound the challenge of controlling toxoplasmosis.

As agricultural practices intensify to meet the demands of growing populations, there is an elevated risk of exposing crops to contamination from infected animal waste or soil. Consumption of raw or undercooked meat from infected animals and untreated water supplies can also harbor Toxoplasma oocysts, perpetuating the cycle of infection.

Proactive Neonatal Screening Programs: Neonatal screening programs for toxoplasmosis have gained prominence as essential components of public health initiatives to mitigate the impact of congenital infections. These proactive initiatives seek to identify infections in newborns early, enabling timely interventions and treatments that can significantly reduce the risk of severe complications associated with toxoplasmosis.

Challenges in Toxoplasmosis Testing Sales Growth: "Evasive Disease Symptoms and Reimbursement Challenges" Toxoplasmosis often manifests with mild flu-like symptoms or no noticeable symptoms at all, posing a unique challenge in disease detection. This inconspicuous nature of the disease can lead to missed opportunities for timely diagnosis and management, referred to as the "lack of symptomatic presentation."

Regulatory approvals and reimbursement policies can impact the adoption of new testing methods. Delays in approvals or challenges in securing reimbursement can slow down the introduction of innovative testing solutions. Availability of rapid and convenient point-of-care tests for toxoplasmosis remains somewhat limited, potentially resulting in delayed diagnosis and treatment in remote or underserved areas.

Country-wise Insights:

United States: The well-established healthcare infrastructure in the United States has created a fertile ground for the growing demand for advanced and specialized testing services, including toxoplasmosis testing. The country places a strong emphasis on preventive care and early disease detection, aligning with the goals of toxoplasmosis testing.

Germany: Routine testing for toxoplasmosis is often included in prenatal screening protocols in Germany to detect infections in pregnant women, allowing for timely interventions to protect maternal and fetal health. Availability of advanced diagnostic technologies enhances the accuracy and efficiency of toxoplasmosis testing in the country.

China: China has witnessed a continuous rise in Toxoplasmosis infections, leading to increased awareness about infectious diseases and the importance of preventive healthcare. Government efforts to improve public health and healthcare services have raised awareness about infectious diseases, contributing to increased demand for toxoplasmosis testing.

Competition Landscape: Companies are focusing on producing high-quality diagnostic test kits while maintaining competitive pricing to expand their market shares. Additionally, manufacturers are running social campaigns to raise awareness about toxoplasmosis diseases, aiming to boost demand for their testing products.

Key Companies Covered:

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc
  • Affymetrix Inc.
  • Beckman Coulter Inc.
  • Biotest
  • Cepheid Inc.
  • GenBio
  • Danaher Corporation
  • Thermo Fisher Scientific
  • Biomerica Inc.
  • Biomerix

Key Segments of Toxoplasmosis Testing Industry Research

Test Type:

  • Serological Tests
    • Dye Tests
    • Indirect Hemagglutination Assays
  • Direct Agglutination Assays
    • ELISA
    • PCR
    • Ultrasound
    • MRI
    • Biopsy

Sample:

  • Blood Samples
  • Amniotic Fluid
  • Cerebrospinal Fluid

End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Toxoplasmosis Testing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Toxoplasmosis Testing Market Outlook, 2018 - 2031

  • 3.1. Global Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Serological Tests
        • 3.1.1.1.1. Dye Tests
        • 3.1.1.1.2. Indirect Hemagglutination Assays
        • 3.1.1.1.3. Direct Agglutination Assays
      • 3.1.1.2. ELISA
      • 3.1.1.3. PCR
      • 3.1.1.4. Ultrasound
      • 3.1.1.5. MRI
      • 3.1.1.6. Biopsy
  • 3.2. Global Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Blood Samples
      • 3.2.1.2. Amniotic Fluid
      • 3.2.1.3. Cerebrospinal Fluid
  • 3.3. Global Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospitals
      • 3.3.1.2. Clinics
      • 3.3.1.3. Diagnostic Laboratories
  • 3.4. Global Toxoplasmosis Testing Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Toxoplasmosis Testing Market Outlook, 2018 - 2031

  • 4.1. North America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Serological Tests
        • 4.1.1.1.1. Dye Tests
        • 4.1.1.1.2. Indirect Hemagglutination Assays
        • 4.1.1.1.3. Direct Agglutination Assays
      • 4.1.1.2. ELISA
      • 4.1.1.3. PCR
      • 4.1.1.4. Ultrasound
      • 4.1.1.5. MRI
      • 4.1.1.6. Biopsy
  • 4.2. North America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Blood Samples
      • 4.2.1.2. Amniotic Fluid
      • 4.2.1.3. Cerebrospinal Fluid
  • 4.3. North America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospitals
      • 4.3.1.2. Clinics
      • 4.3.1.3. Diagnostic Laboratories
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Toxoplasmosis Testing Market Outlook, 2018 - 2031

  • 5.1. Europe Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Serological Tests
        • 5.1.1.1.1. Dye Tests
        • 5.1.1.1.2. Indirect Hemagglutination Assays
        • 5.1.1.1.3. Direct Agglutination Assays
      • 5.1.1.2. ELISA
      • 5.1.1.3. PCR
      • 5.1.1.4. Ultrasound
      • 5.1.1.5. MRI
      • 5.1.1.6. Biopsy
  • 5.2. Europe Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Blood Samples
      • 5.2.1.2. Amniotic Fluid
      • 5.2.1.3. Cerebrospinal Fluid
  • 5.3. Europe Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Clinics
      • 5.3.1.3. Diagnostic Laboratories
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Toxoplasmosis Testing Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Serological Tests
        • 6.1.1.1.1. Dye Tests
        • 6.1.1.1.2. Indirect Hemagglutination Assays
        • 6.1.1.1.3. Direct Agglutination Assays
      • 6.1.1.2. ELISA
      • 6.1.1.3. PCR
      • 6.1.1.4. Ultrasound
      • 6.1.1.5. MRI
      • 6.1.1.6. Biopsy
  • 6.2. Asia Pacific Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Blood Samples
      • 6.2.1.2. Amniotic Fluid
      • 6.2.1.3. Cerebrospinal Fluid
  • 6.3. Asia Pacific Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Clinics
      • 6.3.1.3. Diagnostic Laboratories
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Toxoplasmosis Testing Market Outlook, 2018 - 2031

  • 7.1. Latin America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Serological Tests
        • 7.1.1.1.1. Dye Tests
        • 7.1.1.1.2. Indirect Hemagglutination Assays
        • 7.1.1.1.3. Direct Agglutination Assays
      • 7.1.1.2. ELISA
      • 7.1.1.3. PCR
      • 7.1.1.4. Ultrasound
      • 7.1.1.5. MRI
      • 7.1.1.6. Biopsy
  • 7.2. Latin America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Blood Samples
      • 7.2.1.2. Amniotic Fluid
      • 7.2.1.3. Cerebrospinal Fluid
  • 7.3. Latin America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Clinics
      • 7.3.1.3. Diagnostic Laboratories
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Toxoplasmosis Testing Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Serological Tests
        • 8.1.1.1.1. Dye Tests
        • 8.1.1.1.2. Indirect Hemagglutination Assays
        • 8.1.1.1.3. Direct Agglutination Assays
      • 8.1.1.2. ELISA
      • 8.1.1.3. PCR
      • 8.1.1.4. Ultrasound
      • 8.1.1.5. MRI
      • 8.1.1.6. Biopsy
  • 8.2. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Blood Samples
      • 8.2.1.2. Amniotic Fluid
      • 8.2.1.3. Cerebrospinal Fluid
  • 8.3. Middle East & Africa Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Clinics
      • 8.3.1.3. Diagnostic Laboratories
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By End User vs by Sample Heatmap
  • 9.2. Manufacturer vs by Sample Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Abbott Laboratories
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Bio-Rad Laboratories Inc
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Amazon Renewed
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Affymetrix Inc.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Beckman Coulter Inc.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Biotest
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Cepheid Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. GenBio
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Danaher Corporation
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Thermo Fisher Scientific
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Biomerica Inc.
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Biomerix
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!